PyrAmes

Industry
Digital Health
Founded Year
2016
Headquarters
21730 Stevens Creek Blvd, Suite 201A, Cupertino, CA 95014
Employee Count
10

Key People

Assessment

Team
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with over a decade in their respective fields.

The leadership team at PyrAmes includes individuals with significant experience in medical technology and business development. For instance, CEO Xina Quan has a strong background in health technology, and COO Will Sutherland brings operational expertise. This combination enhances the company's ability to navigate the complexities of the digital health market.

Clinical Need
Aspect: Very Strong
Summary: There is a critical need for non-invasive, continuous blood pressure monitoring, especially in neonatal care.

Traditional methods for continuous blood pressure monitoring in neonates involve invasive arterial catheters, which carry risks of complications. PyrAmes' Boppli device offers a non-invasive alternative, fulfilling a pressing clinical need and potentially improving patient outcomes in neonatal intensive care units.

Competition
Aspect: First mover
Summary: PyrAmes appears to be among the first to offer non-invasive, continuous blood pressure monitoring solutions.

The market for non-invasive, continuous blood pressure monitoring is relatively nascent. PyrAmes' early entry with FDA-cleared products positions the company favorably against potential competitors who may still be in development stages.

Technical Challenge
Aspect: Predictable
Summary: The technology involves moderate complexity with predictable development pathways.

Developing non-invasive, continuous monitoring devices requires integrating sensor technology with data analytics. PyrAmes' successful FDA clearance indicates that the company has effectively addressed these technical challenges, suggesting a predictable path for future product development.

Patent
Aspect: Strong
Summary: PyrAmes holds strong patents protecting its innovative technology.

The company's proprietary technology for non-invasive blood pressure monitoring is protected by strong patents, which can deter competitors and provide leverage in the market. This intellectual property is a valuable asset for PyrAmes.

Financing
Aspect: Well-funded
Summary: PyrAmes has secured significant funding from reputable investors.

The company completed a $6 million Series A financing round led by GSR Ventures, with participation from Keytone Ventures and XTX Ventures. This funding enables PyrAmes to advance product development, conduct clinical validation studies, and pursue regulatory approvals.

Regulatory
Aspect: 510k/PMA
Summary: PyrAmes has achieved FDA 510(k) clearance for its lead product.

The FDA's 510(k) clearance for Boppli indicates that the device meets safety and efficacy standards, allowing PyrAmes to market the product in the U.S. This regulatory milestone is crucial for commercialization and building trust with healthcare providers.

Opportunity Rollup

Odds of Success
4.2
Peak Market Share
6.05
Segment CAGR
3.6%
Market Segment
Patient Monitoring
Market Sub Segment
Non-invasive Blood Pressure Monitoring
Year Post Launch Market Penetration (%)
1 0.30
2 0.91
3 2.12
4 4.24
5 6.05

Key Takeaway

PyrAmes is well-positioned to capitalize on the growing demand for non-invasive, continuous blood pressure monitoring, particularly in neonatal care, supported by strong leadership, robust funding, and FDA-cleared technology.